JP2018520679A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520679A5 JP2018520679A5 JP2017568207A JP2017568207A JP2018520679A5 JP 2018520679 A5 JP2018520679 A5 JP 2018520679A5 JP 2017568207 A JP2017568207 A JP 2017568207A JP 2017568207 A JP2017568207 A JP 2017568207A JP 2018520679 A5 JP2018520679 A5 JP 2018520679A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- recombinant cell
- intracellular signaling
- protein
- cell according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 108091008042 inhibitory receptors Proteins 0.000 claims description 18
- 102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 claims description 17
- 108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 claims description 17
- 108091005703 transmembrane proteins Proteins 0.000 claims description 13
- 102000035160 transmembrane proteins Human genes 0.000 claims description 13
- 230000004068 intracellular signaling Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 230000005965 immune activity Effects 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 230000001461 cytolytic effect Effects 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 21
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 206010010144 Completed suicide Diseases 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 230000001146 hypoxic effect Effects 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 102000004039 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562186108P | 2015-06-29 | 2015-06-29 | |
| US62/186,108 | 2015-06-29 | ||
| PCT/US2016/040010 WO2017004150A1 (en) | 2015-06-29 | 2016-06-29 | Immune checkpoint chimeric antigen receptors therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018520679A JP2018520679A (ja) | 2018-08-02 |
| JP2018520679A5 true JP2018520679A5 (enExample) | 2019-08-08 |
Family
ID=57609024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568207A Pending JP2018520679A (ja) | 2015-06-29 | 2016-06-29 | 免疫チェックポイントキメラ抗原受容体療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180185434A1 (enExample) |
| EP (1) | EP3313892A4 (enExample) |
| JP (1) | JP2018520679A (enExample) |
| KR (1) | KR20180038447A (enExample) |
| CN (1) | CN108137707A (enExample) |
| AU (1) | AU2016285859A1 (enExample) |
| CA (1) | CA2991040A1 (enExample) |
| HK (2) | HK1255637A1 (enExample) |
| IL (1) | IL256643A (enExample) |
| MA (1) | MA42272A (enExample) |
| MX (1) | MX2018000278A (enExample) |
| WO (1) | WO2017004150A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2948544A4 (en) | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
| NZ714555A (en) | 2013-09-17 | 2020-03-27 | Obi Pharma Inc | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
| SG11201609118RA (en) | 2014-05-15 | 2016-11-29 | Univ Singapore | Modified natural killer cells and uses thereof |
| PT3298033T (pt) | 2015-05-18 | 2020-09-22 | Tcr2 Therapeutics Inc | Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão |
| MA42902A (fr) * | 2015-07-08 | 2018-05-16 | Univ Johns Hopkins | Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car) |
| US10590169B2 (en) * | 2015-12-09 | 2020-03-17 | Virogin Biotech Canada Ltd | Compositions and methods for inhibiting CD279 interactions |
| US11365237B2 (en) * | 2016-03-23 | 2022-06-21 | Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Fusion proteins of PD-1 and 4-1BB |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| EP3445395A4 (en) | 2016-04-22 | 2019-12-25 | OBI Pharma, Inc. | CANCER IMMUNOTHERAPY BY MEANING OR IMMUNULATING VIA ANTIGENS OF THE GLOBO SERIES |
| KR20190067765A (ko) | 2016-07-27 | 2019-06-17 | 오비아이 파머 인코퍼레이티드 | 면역원성/치료 글리칸 조성물 및 그의 용도 |
| EP3491026A4 (en) | 2016-07-29 | 2020-07-29 | OBI Pharma, Inc. | HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS |
| CA3044274A1 (en) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| KR20190096969A (ko) * | 2016-12-22 | 2019-08-20 | 윈드밀 테라퓨틱스, 인크. | 면역계를 조절하기 위한 조성물 및 방법 |
| RU2019128544A (ru) | 2017-03-27 | 2021-04-28 | Нэшнл Юниверсити Оф Сингапур | Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров |
| CN110636851B (zh) | 2017-03-27 | 2023-11-03 | 新加坡国立大学 | 截短的nkg2d嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| US10934336B2 (en) | 2017-04-13 | 2021-03-02 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy |
| CA3089170A1 (en) | 2018-02-09 | 2019-08-15 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| SG11202104637VA (en) * | 2018-11-30 | 2021-06-29 | Windmil Therapeutics Inc | MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY |
| SG11202109057XA (en) | 2019-03-05 | 2021-09-29 | Nkarta Inc | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| WO2022098985A1 (en) * | 2020-11-05 | 2022-05-12 | Windmil Therapeutics, Inc. | Glioblastoma specific marrow infiltrating lymphocytes and uses thereof |
| IL302947A (en) * | 2020-11-19 | 2023-07-01 | Obi Pharma Inc | Active cancer immunotherapy by immune modulation via globo series antigens |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3915588A1 (en) | 2011-07-29 | 2021-12-01 | The Trustees of the University of Pennsylvania | Switch costimulatory receptors |
| US9688740B2 (en) * | 2011-10-26 | 2017-06-27 | National Cancer Center | Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| CN105378067A (zh) | 2013-05-13 | 2016-03-02 | 塞勒克提斯公司 | 工程化用于免疫治疗的高活性t细胞的方法 |
| US10287354B2 (en) * | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| EP3174546B1 (en) | 2014-07-31 | 2019-10-30 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
| WO2016037054A1 (en) * | 2014-09-04 | 2016-03-10 | The Johns Hopkins University | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions |
| CA2989949A1 (en) * | 2015-06-19 | 2016-12-22 | Sebastian KOBOLD | Pd-1-cd28 fusion proteins and their use in medicine |
-
2016
- 2016-06-29 JP JP2017568207A patent/JP2018520679A/ja active Pending
- 2016-06-29 EP EP16818647.6A patent/EP3313892A4/en not_active Withdrawn
- 2016-06-29 CA CA2991040A patent/CA2991040A1/en not_active Abandoned
- 2016-06-29 WO PCT/US2016/040010 patent/WO2017004150A1/en not_active Ceased
- 2016-06-29 KR KR1020187002679A patent/KR20180038447A/ko not_active Withdrawn
- 2016-06-29 MA MA042272A patent/MA42272A/fr unknown
- 2016-06-29 HK HK18114773.4A patent/HK1255637A1/zh unknown
- 2016-06-29 US US15/740,981 patent/US20180185434A1/en not_active Abandoned
- 2016-06-29 HK HK18113910.0A patent/HK1254820A1/zh unknown
- 2016-06-29 MX MX2018000278A patent/MX2018000278A/es unknown
- 2016-06-29 AU AU2016285859A patent/AU2016285859A1/en not_active Abandoned
- 2016-06-29 CN CN201680048831.3A patent/CN108137707A/zh active Pending
-
2017
- 2017-12-28 IL IL256643A patent/IL256643A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520679A5 (enExample) | ||
| JP7026161B2 (ja) | 免疫調節性融合タンパク質およびその使用 | |
| van Montfoort et al. | NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines | |
| Mitra et al. | Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps | |
| Prosser et al. | Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1: CD28 chimeric receptor | |
| Geller et al. | Use of allogeneic NK cells for cancer immunotherapy | |
| JP2017522862A5 (enExample) | ||
| IL292650B2 (en) | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2 | |
| Barber et al. | Chimeric NKG2D receptor–expressing T cells as an immunotherapy for multiple myeloma | |
| Sehgal et al. | Programmed death-1 checkpoint blockade in acute myeloid leukemia | |
| RU2016143381A (ru) | Способ и композиции для клеточной иммунотерапии | |
| JP2016520074A5 (enExample) | ||
| JP2017515464A5 (enExample) | ||
| JP2020512284A5 (enExample) | ||
| JP2017513478A5 (enExample) | ||
| JP2017535292A5 (enExample) | ||
| CN112055717B (zh) | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 | |
| JP2018029594A5 (enExample) | ||
| JP2018508219A5 (enExample) | ||
| JP2018522592A5 (enExample) | ||
| RS63574B1 (sr) | Metode za povećanje efikasnosti imuno ćelija | |
| FI3909972T3 (fi) | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä | |
| JP2016534717A5 (enExample) | ||
| JP2019518460A5 (enExample) | ||
| Tang et al. | CD137 co-stimulation improves the antitumor effect of LMP1-specific chimeric antigen receptor T cells in vitro and in vivo |